PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients

SOUTH PLAINFIELD, N.J., May 17, 2023. PTC Therapeutics, Inc. today announced that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric patients with phenylketonuria...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials